Neonatal lupus erythematosus

Last updated
Neonatal lupus erythematosus
Specialty Neonatology, Immunology

Neonatal lupuserythematosus is an autoimmune disease in an infant born to a mother with anti-Ro/SSA and with or without anti-La/SSB antibodies. [1] [2] The disease most commonly presents with a rash resembling subacute cutaneous lupus erythematosus and can have systemic abnormalities such as complete heart block or hepatosplenomegaly. [3] Neonatal lupus is usually benign and self-limited. [3] Many of the clinical manifestations are transient, but certain heart problems can be permanent. [4] Diagnosis is based on maternal antibodies and clinical manifestations. [1] Treatment and management is mainly supportive and focused on preventing complete heart block if possible. [5]

Contents

Pathogenesis

Ro/SSA and La/SSB are proteins found inside cells. Anti-Ro/SSA and anti-La/SSB are antibodies that form against these proteins. These antibodies can be seen in autoimmune diseases, the most common being Lupus and Sjögren's. Mothers can have these antibodies circulating in their blood without having any signs or symptoms of an autoimmune disease.

Babies born to mothers with these antibodies have a chance of developing neonatal lupus erythematosus. [1] This occurs when maternal anti-Ro/SSA and anti-La/SSB antibodies enter fetal circulation and affect neonatal organs by crossing the placenta using FcRn receptors. The mechanism in which the antibodies affect organs is not yet completely understood. For the heart, it is thought that these antibodies bind to cells in the heart that go through physiologic cell death during embryogenesis. This leads to heart cell injury which causes secondary fibrosis in the conduction system, ultimately causing heart block. [2] These antibodies can also affect calcium channels which are needed to initiate action potentials. Disruption to action potential propagation can affect the AV and SA nodes which are part of the conduction system of the heart. [1] [2]

Fetal susceptibility and environmental factors could also play a role in pathogenesis since not all infants develop congenital heart block even when exposed to antibodies. [2]

Clinical manifestations

Neonatal lupus can present with several signs and symptoms. The most common manifestations involve the heart and skin. Problems involving the liver, gallbladder, brain, and blood can be seen but are usually transient. [1]

Heart

Cardiac manifestations present more commonly in utero, but can also present after birth. The most common complications are varying degrees of heart block and endocardial fibroelastosis. A large percentage of infants diagnosed with isolated congenital heart block are associated to neonatal lupus. [2] Heart block occurs when there is dysfunction in the conduction system, preventing impulses from traveling from the atria to the ventricles. [6] Heart block can initially present with bradycardia in the prenatal period, usually around the second trimester. Infants with lower grades of heart block can progress to higher grades, but they can also present with rapid onset of complete heart block. [2] It has been suggested that atrioventricular heart block occurs between 18 and 26 weeks of pregnancy when type A or type B auto antigens migrate to the surface of cardiomyocytes after maternal antibodies bind to the fetal cardiac tissue, triggering fibrosis of the atrioventricular node. [7] Endocardial fibroelastosis is considered a type of cardiomyopathy that occurs in response to heart cell injury and can be seen with or without conduction system dysfunction. [8]

Common complications

Other complications seen with neonatal lupus

Skin

A rash can be seen upon delivery. It is commonly found on the head and face, but can also be found on other parts of the body. It is most commonly seen around the eyes. The rash can be described as raised, red, and ring-shaped. The rash is not always visible at birth and can become more prominent after UV light exposure. Antibodies coming from the mother have a certain life span. Because of this, the rash usually lasts 6–8 months, resolving after the maternal antibodies are no longer in circulation. Telangiectasia has also been seen and can occur with or without the ring-shaped rash. [1] Severe rashes can blister, crust, become hyperpigmented, scar, and in rare cases lead to atrophy; rash management includes limiting sun exposure, wearing protective clothing, and if needed, laser-therapy to reduce telangiectasia. [9]

Liver and gallbladder

Severity in which the liver is affected can range from mildly elevated liver enzymes to liver failure. [1] [2] [4]

Blood

The conditions listed below have been reported with no issues of bleeding or sepsis. [1] [2] [4]

Brain

Although the conditions below have been reported, it is still uncertain that these manifestations are related to anti-Ro/SSA and anti-La/SSB antibodies. [1] Majority of the neurologic conditions were found incidentally with no neurological signs or symptoms present and did not lead to physical disability or need for surgery. [1] [2]

Diagnosis

An infant is diagnosed with neonatal lupus if maternal antibodies, anti-Ro/SSA, anti-La/SSB, or less commonly anti-ribonucleoprotein, are present and if any of the clinical manifestations are present without any other explanation. [1]

Screening

Screening includes testing for maternal antibodies and evaluating for heart block in utero. Universal screening is not recommended. [1] [2] Screening is usually performed when there is a higher likelihood for neonatal lupus such as individuals who are more likely to have antibodies due to autoimmune diseases or individuals who have had prior pregnancies complicated with neonatal lupus. If a fetus develops heart block, screening for maternal antibodies can be considered. Monitoring for heart block can be done using a fetal echocardiogram. [1]

Management

Infants with neonatal lupus are managed with supportive care. This means treating or monitoring the symptoms that can occur from this disease. For example, avoiding sunlight so that the infant's rash won't worsen. Many of the manifestations are transient, but once complete heart block occurs, it is irreversible. Heart block can be managed in utero if diagnosed during pregnancy. Complete heart block (CHB) carries a 9-25% risk of fetal demise; once it has onset, most children will require a pacemaker, and they face the possibility of developing heart failure due to CHB-related cardiomyopathy. [10] Infants born to mothers with anti-Ro/SSA and anti-La/SSB should have an ECG performed to check for heart abnormalities if none were seen while in the uterus. [5]

In utero

Fetal heart block treatment varies based on the degree. First degree heart block is usually treated with glucocorticoids, but it can also reverse on its own. As of right now, treatment guidelines for first-degree heart block is controversial due to lack of evidence. Second degree heart block commonly progresses to complete heart block. Second degree heart block can also reverse on its own. Treatment includes fluorinated glucocorticoids and immunoglobulin therapy. Third degree heart block is irreversible, and many treatments have been attempted without success. Management is mainly expectant. Early delivery should be avoided unless other complications arise. In third degree heart block, if the ventricular heart rate drops below 50-55 beats per minute, maternal beta-antagonists can be given. Glucocorticoids and immunoglobulin therapy can be used for endocardial fibroelastosis, but effectiveness is still unclear. [5]

See also

Related Research Articles

<span class="mw-page-title-main">Antinuclear antibody</span> Autoantibody that binds to contents of the cell nucleus

Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign proteins (antigens) but not to human proteins (autoantigens). In some cases, antibodies to human antigens are produced; these are known as autoantibodies.

<span class="mw-page-title-main">Third-degree atrioventricular block</span> Medical condition

Third-degree atrioventricular block is a medical condition in which the electrical impulse generated in the sinoatrial node in the atrium of the heart can not propagate to the ventricles.

<span class="mw-page-title-main">Lev's disease</span> Medical condition

Lev's disease, also known as Lenegre disease, is an idiopathic disease that can result in a complete heart block, or an extremely slowed heart rate, in patients with this condition. It is thought that for certain patients, this impairment of heart's electrical conduction system is due to fibrosis and calcification of conduction cells. This disease is considered to be age related, with increasing decline seen in elderly patients.

<span class="mw-page-title-main">Malar rash</span> Red, scaly rash of the cheeks and bridge of the nose

A malar rash, also called butterfly rash, is a medical sign consisting of a characteristic form of facial rash. It is often seen in lupus erythematosus. More rarely, it is also seen in other diseases, such as pellagra, dermatomyositis, and Bloom syndrome.

<span class="mw-page-title-main">Hemolytic disease of the newborn</span> Fetal and neonatal alloimmune blood condition

Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis fetalis, is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules produced by the mother pass through the placenta. Among these antibodies are some which attack antigens on the red blood cells in the fetal circulation, breaking down and destroying the cells. The fetus can develop reticulocytosis and anemia. The intensity of this fetal disease ranges from mild to very severe, and fetal death from heart failure can occur. When the disease is moderate or severe, many erythroblasts are present in the fetal blood, earning these forms of the disease the name erythroblastosis fetalis.

<span class="mw-page-title-main">CREST syndrome</span> Connective tissue disorder

CREST syndrome, also known as the limited cutaneous form of systemic sclerosis (lcSSc), is a multisystem connective tissue disorder. The acronym "CREST" refers to the five main features: calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.

<span class="mw-page-title-main">Atrioventricular septal defect</span> Medical condition

Atrioventricular septal defect (AVSD) or atrioventricular canal defect (AVCD), also known as "common atrioventricular canal" or "endocardial cushion defect" (ECD), is characterized by a deficiency of the atrioventricular septum of the heart that creates connections between all four of its chambers. It is a very specific combination of 3 defects:

Extractable nuclear antigens (ENAs) are over 100 different soluble cytoplasmic and nuclear antigens. They are known as "extractable" because they can be removed from cell nuclei using saline and represent six main proteins: Ro, La, Sm, RNP, Scl-70, Jo1. Most ENAs are part of spliceosomes or nucleosomes complexes and are a type of small nuclear ribonucleoprotein (snRNPS). The location in the nucleus and association with spliceosomes or nucleosomes results in these ENAs being associated with additional RNA and proteins such as polymerases. This quality of ENAs often makes it difficult to purify and quantify their presence for clinical use.

Endocardial fibroelastosis (EFE) is a rare heart disorder usually occurring in children two years old and younger. It may also be considered a reaction to stress, not necessarily a specific disease.

Mixed connective tissue disease (MCTD) is a systemic autoimmune disease that shares characteristics with at least two other systemic autoimmune diseases, including systemic sclerosis (Ssc), systemic lupus erythematosus (SLE), polymyositis/dermatomyositis (PM/DM), and rheumatoid arthritis. The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., and the term was introduced by Leroy in 1980.

<span class="mw-page-title-main">HLA-DR11</span>

HLA-DR11 (DR11) is a HLA-DR serotype that recognizes the DRB1*1101 to *1110. DR11 serotype is a split antigen of the older HLA-DR5 serotype group which also contains the similar HLA-DR12 antigens.

<span class="mw-page-title-main">TRIM21</span> Protein-coding gene in the species Homo sapiens

Tripartite motif-containing protein 21, also known as E3 ubiquitin-protein ligase TRIM21, is a protein that in humans is encoded by the TRIM21 gene. Alternatively spliced transcript variants for this gene have been described but the full-length nature of only one has been determined. It is expressed in most human tissues.

<span class="mw-page-title-main">Lupus erythematosus</span> Collection of human autoimmune diseases

Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs. The most common and most severe form is systemic lupus erythematosus.

Subacute cutaneous lupus erythematosus is a clinically distinct subset of cases of lupus erythematosus that is most often present in white women aged 15 to 40, consisting of skin lesions that are scaly and evolve as poly-cyclic annular lesions or plaques similar to those of plaque psoriasis.

<span class="mw-page-title-main">Lupus</span> Autoimmune disease in which the immune system attacks healthy tissue

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. Children up to 18 years old develop a more severe form of SLE termed childhood-onset systemic lupus erythematosus.

<span class="mw-page-title-main">Anti-SSA/Ro autoantibodies</span> Type of anti-nuclear autoantibodies

Anti-SSA autoantibodies are a type of anti-nuclear autoantibodies that are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis. They are often present in Sjögren's syndrome (SS). Additionally, Anti-Ro/SSA can be found in other autoimmune diseases such as systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD), and are also associated with heart arrhythmia.

Lupus and pregnancy can present some particular challenges for both mother and child.

Eldad Ben-Chetrit is a professor of Medicine, former Head of the Department of Medicine and former director of the Rheumatology unit (2009-2017) at the Hadassah-Hebrew University Medical Center in Jerusalem. He was a visiting professor at the Oklahoma Medical Research Foundation (1996), at the Biochemistry Department, Stanford University (2004), and at the Gaslini Children Hospital, University of Genoa, Italy, and the Tropical Medicine Clinic, University of Heidelberg, Germany (2016).

<span class="mw-page-title-main">Congenital heart block</span> Medical condition

The congenital heart block (CHB) is the heart block that is diagnosed in fetus or within the first 28 days after birth, some studies also include the diagnosis during early childhood to the definition of CHB. It refers to the disorder in the electrical conduction system within the heart muscle, which leads to the failure in pumping the blood efficiently into the aorta and the pulmonary trunk. The result of CHB can be first, second, or third-degree (complete) atrioventricular block in which no electric signals move from the atrium to the ventricles

Childhood-onset systemic lupus erythematosus, also termed juvenile-onset systemic lupus erythematosus, juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, is a form of the chronic inflammatory and autoimmune disease, systemic lupus erythematosus, that develops in individuals up to 18 years old. Early-onset systemic lupus erythematosus is often used to designate a subset of cSLE patients who are up to 5 years old. Children with early-onset SLE tend to have a more severe form of cSLE than children who develop cSLE after 5 years of age.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 Buyon JP. "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis". UpToDate. Retrieved March 9, 2022.
  2. 1 2 3 4 5 6 7 8 9 10 Wallace DJ, Hahn B (2019). Dubois' lupus erythematosus and related syndromes. Daniel J. Wallace, Bevra Hahn (Ninth ed.). Edinburgh. ISBN   978-0-323-55064-2. OCLC   1051140253.{{cite book}}: CS1 maint: location missing publisher (link)
  3. 1 2 Hon KL, Leung AK (2012). "Neonatal lupus erythematosus". Autoimmune Diseases. 2012: 301274. doi: 10.1155/2012/301274 . PMC   3437607 . PMID   22973504.
  4. 1 2 3 Tsokos GC (2020). Systemic lupus erythematosus : basic, applied and clinical aspects (Second ed.). London. ISBN   978-0-12-814552-4. OCLC   1150240738.{{cite book}}: CS1 maint: location missing publisher (link)
  5. 1 2 3 Buyon JP (11 August 2020). "Neonatal Lupus: Management and outcomes". UpToDate. Retrieved March 14, 2022.
  6. ↑ Sauer WH (3 June 2021). Link MS, Yeon SB (eds.). "Etiology of Atrioventricular block". UpToDate. Retrieved March 10, 2022.
  7. ↑ https://www.ncbi.nlm.nih.gov/books/NBK526061/. Diaz-Frias, Josue. “Neonatal Lupus Erythematosus.” StatPearls [Internet]., U.S. National Library of Medicine, 26 June 2023, www.ncbi.nlm.nih.gov/books/NBK526061/.
  8. ↑ Cooper LT. "Definition and classification of the Cardiomyopathies". UpToDate. Retrieved March 10, 2022.
  9. ↑ Vanoni, F., Lava, S.A.G., Fossali, E.F. et al. Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review. Clinic Rev Allerg Immunol 53, 469–476 (2017). https://doi.org/10.1007/s12016-017-8653-0
  10. ↑ Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E, Sammaritano LR, Chambers CD, Buyon J. The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. Rheumatology (Oxford). 2018 Jul 1;57(suppl_5):v9-v17. doi: 10.1093/rheumatology/key141. PMID: 30137589; PMCID: PMC6099126.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.